Anti-cytokine or antioxidant therapy could treat an inflammation-mediated HFpEF by normalizing CaMKII and LTCC function, but HFpEF patients with hypertension as the primary cause would benefit from phenotype-specific Ca2+-handing modulators or myosin light chain kinase (MLCK) inhibitors to enhance relaxation [21]. The gene discussed is MYLK; the disease is Hypertension.